<h4>Background</h4>Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts, was approved for use in patients with relapsed or refractory B-cell precursor ALL on the basis of single-g...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!